<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079295</url>
  </required_header>
  <id_info>
    <org_study_id>1102/2020/Oss/AOUFe</org_study_id>
    <nct_id>NCT05079295</nct_id>
  </id_info>
  <brief_title>Management of Anticoagulants and Antithrombotics in Patients With CSDH</brief_title>
  <acronym>THERCA</acronym>
  <official_title>Thromboembolic and Hemorrhagic Risk Evaluation in Surgically Treated Patients With CSDH Taking Anticoagulants and Antithrombotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study will be to compare, up to 6 months after surgery, number of&#xD;
      relapses (post operative re-bleeding) or intracerebral hemorrhage (others than subdural&#xD;
      hematomas) and thromboembolic or cardiovascular ischemic events, in patients undergoing&#xD;
      surgery for chronic subdural hematoma (CSDH). These data will be correlated to the suspension&#xD;
      or not of antithrombotics or anticoagulants before surgery or their re-introduction after&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">February 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hemorrhagic or thromboembolic events evaluation</measure>
    <time_frame>up to 6 months after surgery</time_frame>
    <description>hemorrhagic (re-bleedings in surgical field, other cerebral bleedings); thromboembolic events(acute ischemic stroke, acute myocardial infarction, pulmunoray embolism, deep venous thrombosis)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <condition>Anticoagulant-induced Bleeding</condition>
  <condition>Thromboembolic Stroke</condition>
  <condition>Cardiovascular Stroke</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients taking anticoagulants or antithrombotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CSDH evacuation</intervention_name>
    <description>Burr hole for chronic subdural hematomas</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients suffering from CSDH which needs surgery for its evacuation. Study group will&#xD;
        be all patients taking anticoagulants or antithrombotics; control group will be all&#xD;
        patients who are not taking these drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Evidence of CSDH which needs surgery&#xD;
&#xD;
          -  patients taking antithrombotics or anticoagulants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous surgery for CSDH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <state>Emilia-Romagna</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alba Scerrati, MD</last_name>
      <phone>+39532236292</phone>
      <email>scrlba@unife.it</email>
    </contact>
    <investigator>
      <last_name>Pasquale De Bonis, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giorgio Mantovani, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Dott.ssa Alba Scerrati</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chronic subdural hematoma</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>antithrombotics</keyword>
  <keyword>thromboembolic disease</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

